Honestly I have not seen this at any other similar or larger size company. Non exec directors no problems as they might sit on various other boards but I find it very strange that CEO is moonlighting at other places given we at a fairly important phase in this company. Beyond ph3 trials, there are partnering discussions DME work and maybe some back burner pre clinical stuff or even co formulation.
The optics of this move don’t sit well IMO besides it’s not like CEO is struggling to make ends meet currently and will be rolling in $$$ if ph3 is successful.
Would be nice if company puts out a disclosure about this.
Analyst Upgrade, page-83
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
0.005(0.93%) |
Mkt cap ! $670.9M | |||
| Open | High | Low | Value | Volume |
| 54.5¢ | 56.0¢ | 53.8¢ | $817.0K | 1.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 619 | 54.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.0¢ | 27532 | 3 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |